242 related articles for article (PubMed ID: 23740727)
1. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.
Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2608-16. PubMed ID: 23740727
[TBL] [Abstract][Full Text] [Related]
2. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
Astvad KMT; Hare RK; Arendrup MC
Clin Microbiol Infect; 2017 Nov; 23(11):882-887. PubMed ID: 28373148
[TBL] [Abstract][Full Text] [Related]
4.
Pfaller MA; Rhomberg PR; Wiederhold NP; Gibas C; Sanders C; Fan H; Mele J; Kovanda LL; Castanheira M
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061288
[TBL] [Abstract][Full Text] [Related]
5. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
Guinea J; Peláez T; Recio S; Torres-Narbona M; Bouza E
Antimicrob Agents Chemother; 2008 Apr; 52(4):1396-400. PubMed ID: 18212101
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
7. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
[TBL] [Abstract][Full Text] [Related]
8. EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates.
Jørgensen KM; Astvad KMT; Hare RK; Arendrup MC
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910898
[TBL] [Abstract][Full Text] [Related]
9. Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity.
Denis J; Ledoux MP; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):8-14. PubMed ID: 29534853
[TBL] [Abstract][Full Text] [Related]
10. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236
[TBL] [Abstract][Full Text] [Related]
11. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.
Pfaller MA; Castanheira M; Messer SA; Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2014 Jun; 79(2):198-204. PubMed ID: 24736096
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect.
Marcos-Zambrano LJ; Gómez A; Sánchez-Carrillo C; Bouza E; Muñoz P; Escribano P; Guinea J
Clin Microbiol Infect; 2018 Dec; 24(12):1343.e1-1343.e4. PubMed ID: 30025834
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.
Pfaller MA; Espinel-Ingroff A; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2011 Mar; 49(3):845-50. PubMed ID: 21227994
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.
Messer SA; Carvalhaes CG; Castanheira M; Pfaller MA
Diagn Microbiol Infect Dis; 2020 May; 97(1):115007. PubMed ID: 32081523
[TBL] [Abstract][Full Text] [Related]
15. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.
Castanheira M; Messer SA; Rhomberg PR; Dietrich RR; Jones RN; Pfaller MA
Mycopathologia; 2014 Aug; 178(1-2):1-9. PubMed ID: 24952015
[TBL] [Abstract][Full Text] [Related]
16. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017).
Desnos-Ollivier M; Bretagne S; Boullié A; Gautier C; Dromer F; Lortholary O;
Clin Microbiol Infect; 2019 May; 25(5):634.e1-634.e4. PubMed ID: 30771532
[TBL] [Abstract][Full Text] [Related]
17. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
18. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).
Messer SA; Jones RN; Fritsche TR
J Clin Microbiol; 2006 May; 44(5):1782-7. PubMed ID: 16672407
[TBL] [Abstract][Full Text] [Related]
19.
Pfaller MA; Huband MD; Flamm RK; Bien PA; Castanheira M
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182527
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]